Sino Biopharmaceutical Limited Stock

Equities

1177

KYG8167W1380

Pharmaceuticals

Market Closed - Hong Kong S.E. 16:08:09 13/06/2025 HKT 5-day change 1st Jan Change
5.530 HKD -2.81% Intraday chart for Sino Biopharmaceutical Limited +21.54% +72.81%

Valuation: Sino Biopharmaceutical Limited

Capitalization 90.47B 98.9B 12.6B 10.9B 10.23B 9.27B 17.11B 1,085B 19.35B 120B 46.51B 497B 47.29B 46.27B 1,814B P/E ratio 2025 *
28.3x
P/E ratio 2026 * 25.3x
Enterprise value 85.19B 93.12B 11.86B 10.26B 9.63B 8.73B 16.11B 1,021B 18.22B 113B 43.8B 468B 44.53B 43.57B 1,708B EV / Sales 2025 *
2.66x
EV / Sales 2026 * 2.27x
Free-Float
51.86%
Yield 2025 *
1.24%
Yield 2026 * 1.37%
More valuation ratios * Estimated data
Dynamic Chart
Sino Biopharmaceutical Updates On Phase III Registrational Clinical Study Of TQB2868 Injection 06-10 RE
Sino Biopharmaceutical Limited Announces Approval Obtained from CDE to Initiate Phase III Registrational Clinical Study of TQB2868 Injection "PD-1/TGF Bi-Functional Fusion Protein" 06-10 CI
Sino Biopharmaceutical Says Tqc3721 Inhalation Suspension Approved By Center For Drug Evaluation 06-09 RE
Sino Biopharmaceutical Limited Presents Latest Results of the Phase III Clinical Study for Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Maintenance Treatment for Non-Small Cell Lung Cancer 06-05 CI
Sino Biopharm Presents Lung Cancer Drug Trial Data at US Oncology Conference 06-05 MT
Sino Biopharmaceutical Limited Presents Latest Results of the Phase III Clinical Study for Benmelstobart in Combination with Anlotinib Hydrochloride Capsules 06-03 CI
Sino Biopharm Presents Lung Cancer Study Data at American Oncology Conference 06-03 MT
Sino Biopharm Presents Cancer Drug Data at Oncology Conference 05-28 MT
Sino Biopharmaceutical Limited Presents the Preliminary Data from the First-In-Human Phase I Clinical Study for TQB2102 05-27 CI
Sino Biopharmaceutical Presents Lung Cancer Drug Trial Data at US Oncology Society Meeting 05-23 MT
Sino Biopharmaceutical Limited Announces Data from Phase III Study of Benmelstobart in Combination with Anlotinib for First-Line Treatment of Sq-NSCLC 05-23 CI
Sino Biopharmaceutical Gets FDA Nod to Market Cancer Drug 04-25 MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Penpulimab Injection by the US FDA 04-25 CI
More news
1 day-2.81%
1 week+21.54%
Current month+24.27%
1 month+38.25%
3 months+56.66%
6 months+67.58%
Current year+72.81%
More quotes
1 week 4.46
Extreme 4.46
5.78
1 month 3.88
Extreme 3.88
5.78
Current year 2.67
Extreme 2.67
5.78
1 year 2.55
Extreme 2.55
5.78
3 years 2.29
Extreme 2.29
5.78
5 years 2.29
Extreme 2.29
11.24
10 years 2.05
Extreme 2.0489
11.24
More quotes
Manager TitleAgeSince
Chief Executive Officer 29 28/07/2022
Director of Finance/CFO 54 01/01/1996
Investor Relations Contact 55 25/04/2013
Director TitleAgeSince
Chairman 73 02/02/2000
Director/Board Member 55 01/08/1995
Director/Board Member 61 10/04/2017
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-2.81%+21.54%+100.36%+34.55% 12.6B
+0.90%+6.43%-6.73%+181.77% 736B
+0.28%+1.34%+7.94%-6.59% 378B
-0.58%+5.27%-47.91%+36.67% 355B
-0.70%+0.66%+13.34%+38.85% 338B
-1.06%+0.56%+8.93%-11.79% 266B
-0.93%+0.08%+2.26%+20.37% 235B
-0.40%+1.89%-12.18%+12.68% 232B
-0.13%+3.47%-36.89%-3.30% 205B
-0.70%+1.68%-1.14%+25.25% 159B
Average -0.61%+4.35%+2.80%+32.84% 291.55B
Weighted average by Cap. -0.15%+3.23%-7.16%+56.83%
See all sector performances

Financials

2025 *2026 *
Net sales 32.05B 35.03B 4.46B 3.86B 3.62B 3.28B 6.06B 384B 6.86B 42.34B 16.48B 176B 16.75B 16.39B 643B 35.29B 38.58B 4.92B 4.25B 3.99B 3.62B 6.68B 423B 7.55B 46.63B 18.15B 194B 18.45B 18.05B 708B
Net income 3.25B 3.55B 452M 391M 367M 332M 614M 38.91B 694M 4.29B 1.67B 17.81B 1.7B 1.66B 65.07B 3.65B 3.99B 508M 440M 413M 374M 690M 43.75B 781M 4.82B 1.88B 20.03B 1.91B 1.87B 73.17B
Net Debt -5.28B -5.78B -736M -637M -597M -541M -1B -63.37B -1.13B -6.98B -2.72B -29.01B -2.76B -2.7B -106B -10.47B -11.45B -1.46B -1.26B -1.18B -1.07B -1.98B -126B -2.24B -13.84B -5.38B -57.49B -5.48B -5.36B -210B
More financial data * Estimated data
Logo Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicine and Chemical Medicine segment is engaged in the manufacture, sale and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is principally engaged in the long term and short term investments. The Other segment is principally engaged in the related medical and hospital business.
Employees
24,379
Calendar
More about the company
Date Price Change Volume
13/06/25 5.530 $ -2.81% 393,835,600
12/06/25 5.690 $ +19.29% 514,830,800
11/06/25 4.770 $ 0.00% 108,016,600
10/06/25 4.770 $ +0.63% 198,398,200
09/06/25 4.740 $ +4.18% 214,332,000

Delayed Quote Hong Kong S.E., June 13, 2025 at 04:08 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
5.059CNY
Average target price
4.511CNY
Spread / Average Target
-10.82%
Consensus

Quarterly revenue - Rate of surprise